The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

Researchers urged hospitals to set up processes for updating pharmacogenomic results, but it's unclear how frequently that ...

NEW YORK – AstraZeneca and Daiichi Sankyo on Friday said the European Commission approved their antibody-drug conjugate Enhertu (trastuzumab deruxtecan) as a treatment for patients with unresectable ...